Apolipoprotein E (ApoE), a major component of blood chylomicrons, very-low-density lipoprotein, and highdensity lipoprotein (HDL) particles, 1e4 has several alleles that differ by point mutations that are associated with a range of clinical phenotypes (Supplemental Table 1 ). As part of a study to assess the genetic variations of medical importance among Qataris, a population that evolved at the migration crossroads of Africa and characterized by a high prevalence of type 2 diabetes mellitus, obesity, and cardiovascular disease, 5, 6 we observed a high frequency of a point mutation in amino acid 145 of ApoE, in which arginine is substituted by cysteine (R145C). Since its discovery in 1982, the mutation has been described in 32 subjects (Supplemental Table 2 ) as inherited in a dominant fashion with incomplete penetrance 7, 8 and hypothesized to be a rare cause of type III hyperlipoproteinemia. The Qatari population is composed of 3 distinct genetic subpopulations, including Arab, Persian, and African (Q3). 5 Recognizing that all the R145C variants were in Qataris of African genetic ancestry, we hypothesized that the R145C polymorphism might be far more common in those of African descent than previously recognized. To assess this, we evaluated the genomes represented by the "1000 Genomes Project" and of 1,012 whites and 1,226 African-Americans in the New York City Metropolitan Area. The prevalence of the mutation in the study population suggests that ApoE R145C might put large numbers of Africans and African descendants worldwide at risk of a mild triglyceride dyslipidemia.
(Doha, Qatar), all participants in Qatar and New York signed informed consent documents for participation in the present study. Three populations were assessed: Qataris (n ¼ 228; subgrouped into 3 distinct genetic subpopulations: Arabian, n ¼ 123; Persian, n ¼ 82; and African [Q3], n ¼ 23), worldwide subjects from the 1000 Genomes Project (n ¼ 1,094), and whites (n ¼ 1,012) and African-Americans (n ¼ 1,226) in the New York metropolitan area (Supplemental Methods).
ApoE variants were identified in the Qatari and New York African-American populations using polymerase chain reaction (Supplemental Table 3 ) and sequencing, when necessary. The ApoE variants in the 1000 Genomes Project data were identified from the single nucleotide polymorphisms and, when available, sequences (Supplemental Methods).
The clinical phenotypes of the Qatari Q3 R145C were identified from a review of medical records, including 4 to 14 fasting lipid profiles within 7 to 9 years (i.e., triglycerides, cholesterol, low-density lipoprotein [LDL] cholesterol, HDL cholesterol; Supplemental Table 4 ). The Q3 R145C subjects were compared with 15 Q3 controls for whom lipid levels were available (1 to 10 fasting lipid profiles within 1 to 9 years).
Of the 53 New York African-American R145C, 23 had fasting routine lipid values available from the medical records (73% with 1 measurement and 27% with 2 to 47 measurements within 2 to 12 years). Of the African-American controls, 72 randomly chosen subjects had fasting lipid studies retrieved from their medical records (71% had 1 study and 29% had 2 to 36 studies within 1 to 12 years). Attempts were made to interview all 53 New York AfricanAmerican R145C subjects. Of these 53, 16 (30%) returned for additional studies. Of these 16, 5 also had previous values available from their medical records. The fasting plasma from these 16 R145C subjects was assessed for lipoprotein subclass profiling, hemoglobin A1C, high-sensitivity C-reactive protein, lipoprotein (a), ApoA1, ApoB, thyroidstimulating hormone, and glucose using proton nuclear magnetic resonance spectroscopy (Liposceince, Raleigh, North Carolina), and for LDL electrophoresis and subfractionation (Berkeley HeartLab, Alameda, Calif).
The fasting lipid studies of the R145C subjects and controls were compared using 2 methods: (1) using all mean values from each subject, with a single-factor analysis of variance (ANOVA) and (2) weighting the mean value for each subject by the variance in mean response, with a nested ANOVA (Supplemental Methods).
Results
ApoE2, ApoE3, and ApoE4 represent >95% of ApoE alleles worldwide. 1, 2 In most populations, ApoE3 is the most common, followed by ApoE4 and then ApoE2 4, 9 ( Figure 1 ). Of the common ApoE alleles in the overall Qatari population, ApoE3 dominated, with ApoE4 more common than ApoE2 (Table 1) . However, in the context of the Qatari genetic subpopulations, 5 the proportion of the common ApoE alleles differed (p <10 À3 , chi-square), with the greatest percentage of the ApoE3 allele in the Persian group (93%), the greatest percentage of the ApoE2 allele in the Q3 (African) group (11%), and the greatest percentage of the ApoE4 allele also in the Q3 group (15%).
Of the 456 Qatari ApoE alleles assessed, 4 (0.9%) had the R145C polymorphism (Table 1 ). All were on the ApoE3 background, all were heterozygotes, and all were in the Q3 4 , resulting in amino acid substitutions at positions 112 and 158, dictating the common ApoE2, ApoE3, and ApoE4 alleles. A C/T transition at single nucleotide polymorphism rs769455, corresponding to amino acid 145 within the positively charged receptor-binding domain, gives rise to alleles ApoE3R145C and ApoE4R145C, depending on whether the R145C variant is on the E3 or E4 allele.
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The American Journal of Cardiology (www.ajconline.org) (African) subpopulation, representing 17.4% of all Q3 subjects. All 4 subjects had type 2 diabetes, all were obese, 1 had cataracts, 2 had cardiovascular disease, and 1 had kidney disease (Supplemental Table 4 ). None had thyroid disease or xanthomas; 3 had hypertriglyceridemia (mean level 193 to 465 mg/dl), 2 of the 4 had hypercholesterolemia, 1 had low HDL cholesterol, and 3 of the 4 had elevated LDL cholesterol. Of the 15 Q3 Qatari controls, 4 (27%) had type 2 diabetes compared with 100% of the Qatari R145C subjects (p <0.04). The incidence of xanthomas, cataracts, hypertension, and thyroid disease was similar in the control group and R145C group (p >0.1, for all comparisons). The Qatari R145C triglyceride levels were significantly greater than those in the Qatari controls (p <0.006, single-factor ANOVA, p <0.007 nested ANOVA). The cholesterol, HDL, and LDL levels were not significantly different between the 2 groups (p >0.2, all comparisons, single-factor or nested ANOVA; Figure 2 ). Assessment of the 1000 Genomes Project populations revealed that 12 of the 97 (12%) Luhya subjects in the Webuye, Kenya population and 7 of the 88 (8%) Yoruban subjects in Ibadan, Nigeria were R145C (Table 2 ). In addition, 3 of 61 (5%) of African ancestry in the Southwest United States population were R145C. The R145C polymorphism was not observed in the British, Finnish, Northern and Western European ancestry, Iberian populations in Spain, Toscani in Italy, Han Chinese in Beijing, China, Han Chinese South, Japanese in Tokyo, Japan, or Colombian in Medellin, Colombia, populations and was only rarely present in the Puerto Rican and Mexican populations (1.5% to 1.8%).
Consistent with our hypothesis, 53 of 1,226 (4.3%) New York African-Americans were R145C heterozygotes (Table 3) . Most were on the ApoE3 allele (ApoE3>> ApoE4). One subject with mixed African-American-Hispanic ancestry (0.1% of the population) had the E4E13 K.R145C allele, novel to the present study. Of the 1,012 whites, none had the R145C polymorphism on the common ApoE2, ApoE3, or ApoE4 alleles. One white subject had the ApoE3E13 K.R145 C allele (ApoE4 Philadelphia , associated with type III hyperlipidemia with incomplete dominance 10 ; Supplemental Tables 1 and 2) .
Of the 53 African-American R145C subjects, no difference was found compared with the 72 African-American controls in age, gender, body mass index, human immunodeficiency virus (HIV) status, or the proportion of those with type 2 diabetes, thyroid disease, or cataracts (p >0.4, for all comparisons). The African-American R145C subjects had 52% greater triglyceride levels than the controls (p <0.001, single-factor ANOVA; p <0.002, nested ANOVA; Figure 2 ; Supplemental Table 5 ). The triglyceride levels remained significantly greater in the R145C group when considering HIV status as a covariate (p <0.007 single factor ANOVA, p <0.003 nested ANOVA). The cholesterol and HDL cholesterol levels of the R145C and control groups were not significantly different (p >0.1, both comparisons, single-factor or nested ANOVA, with and without considering HIV status). The LDL cholesterol levels were borderline lower in the R145C subjects (p <0.03, single-factor ANOVA; p >0.06, nested ANOVA; p <0.03, single-factor ANOVA, and p >0.1, nested ANOVA when considering HIV status). Of the subgroup of AfricanAmerican R145C subjects with average triglyceride levels greater than the normal range (>150 mg/dl), the average lipid profile included triglycerides 276 AE 98 mg/dl, cholesterol 198 AE 29 mg/dl, LDL cholesterol 96 AE 25 mg/dl, and HDL cholesterol 43 AE 15 mg/dl.
Of the 53 African-American R145C subjects, 16 were available for additional fasting lipid analysis (Supplemental Table 6 ). The most striking observation was an increase in the levels of small very-low-density lipoprotein particle levels and HDL particle size (31% and 38% of the population studied, respectively). To a variable degree, some of the R145C subjects had an increase in the levels of LDL particles and HDL particles. LDL gel electrophoresis identified 31% of R145C subjects with an LDL IIIa þ b peak in the intermediate or high cardiovascular risk range. Finally, 25% of the R145C subjects had elevated levels of LDL 
Data are presented as n (%) of the population. * The DNA for all Qataris was first assessed using TaqMan polymerase chain reaction at single nucleotide polymorphisms rs429358 (amino acid 112), rs769455 (amino acid 145), and rs7412 (amino acid 158). This was followed by sequencing of all ApoE exons and flanking introns. If heterozygosity was present at 2 single nucleotide polymorphisms in the same subject, cloning and complete sequencing was performed to unambiguously identify the genotype.
† The E5 allele (E212K on the E3 background) has been previously described 10 ; this subject had no dyslipidemia. z The E2R150H (R150H substitution on the E2 background) allele was novel to the present study; this subject had no dyslipidemia.
x See Supplemental particles, 50% had elevated lipoprotein (a) levels, 44% had elevated ApoA1 levels, and 31% had high-sensitivity Creactive protein levels in the high-risk range.
Discussion
Discovered in the early 1970s as a constituent of verylow-density lipoprotein, ApoE is a polymorphic protein also found in chylomicrons, HDL, and remnant particles of chylomicrons and very-low-density lipoprotein. ApoE plays an important role in the overall maintenance of cholesterol homeostasis by stabilization of these particles in the circulation and enhancing uptake by the liver and other tissues.
1e3,12 ApoE also participates in cholesterol efflux from macrophages, 13, 14 prevents platelet aggregation, 15 and inhibits endothelial cell and T-lymphocyte proliferation. 15e17 The ApoE knockout mouse has been used as an in vivo model for atherosclerosis. 18 The LDL receptor binds to ApoE3 with high affinity; this is markedly lower with ApoE2, which has only 2% the binding affinity of ApoE3 and ApoE4. 19 Only 1% to 10% of ApoE2/ApoE2 homozygotes will develop type III hyperlipoproteinemia. 3, 8, 20 In addition to the common ApoE2, ApoE3, and ApoE4 alleles, 38 rare ApoE variants have been identified, associated with a range of clinical phenotypes, including dyslipidemias and the risk of cardiovascular disease 3 (Supplemental Table 1 ). Of these rare variants, R145C has been reported in 32 cases in the past 3 decades, all in subjects treated in lipid-related clinics or their families (Supplemental Table 2 ), and has been described as a dominant mutation with incomplete penetrance in association with familial type III hyperlipidemia. 7, 8 The R145C variant reduces the positive charge of this domain, 8, 21 because it has 40% of the binding affinity of ApoE3 to the LDL receptor. 8, 21 This discrepancy in disease manifestation might be explained by considering the role of other ApoE receptors in the clearance of remnant particles from the circulation, including the LDL-like receptor and heparin sulfate proteoglycans. 3, 8, 12 Although the R145C variant has better binding affinity to the LDL receptor than ApoE2, it binds much more poorly to heparin sulfate In a study investigating the genetic variations of the Qatari genome, the assessment of 228 Qataris identified that 4 of 23 (17%) with a Q3 (Sub-Saharan African) genetic background were heterozygotes for the R145C polymorphism on the ApoE3 background. In contrast, Qataris from an Arabian or Persian genetic subgroup did not have this ApoE variation. This led to the hypothesis that the ApoE R145C variant might be prevalent in African-derived populations and, if so, could be a risk factor for dyslipidemia far more common than would be expected from the rare reports of this variant in the published data. This was verified by assessment of the May 2011 release of the 1000 Genomes Project data, demonstrating that the R145C variant is rare to nonexistent in populations that are not African or descended from African populations but common (5% to 12%) among African-derived populations.
This observation was further confirmed in subjects randomly recruited in the New York Metropolitan area for a study on smoking-related lung health. The data demonstrated that, although rare (0.1%) in the white population, 4.3% of African-Americans in the New York Metropolitan region were heterozygous for the R145C allele. On the average, the New York African-American R145C subject had fasting dyslipidemia, with fasting triglyceride levels 52% greater than those of matched New York AfricanAmerican controls. Consistent with the dominant, incomplete penetrance of this at-risk allele, variable proportions of the African-American R145C subjects also had elevated levels of very-low-density lipoprotein, LDL, and HDL particles; elevated levels of ApoA1, lipoprotein (a), and high-sensitivity C-reactive protein at the high risk ranges; and an elevated LDL gel electrophoresis IIIa þ b peak in the intermediate and high cardiovascular risk range. The high rate of R145C among Q3 Qataris compared with that of the 1000 Genomes Project African-descendant populations or the New York African-American subjects might have resulted from the Q3 disassortative mating pattern that exceeds that of other African-descendant groups and leads to a greater frequency of heterozygosity. 5, 22 From the available data, it is clear that the R145C variant carries an increased risk of dyslipidemia; however, the extent of that risk is not clear. All previous descriptions of the R145C allele have been in subjects identified in lipid clinics or their family members (Supplemental Table 2 ; see also Supplemental Methods for ApoE Nomenclature). No studies have been published of the prevalence of the R145C variant among different populations. There appears to be no increased risk of R145C homozygosity compared with heterozygosity; most cases have been associated with elevated levels of triglycerides and cholesterol and low levels of HDL cholesterol and, in some, xanthomas and/or cardiovascular disease (Supplemental Table 2 ). The overall consensus has been that the R145C variant conveys increased risk inherited in a dominant fashion with incomplete penetrance, 7 likely dependent on environmental factors.
Of the Qatari R145C subjects, the triglyceride levels were significantly greater than those of the control group; however, no significant differences were found in the cholesterol, HDL cholesterol, or LDL cholesterol levels between the 2 groups. All 4 were obese and had diabetes, 2 had cardiovascular disease, 3 had hypertension, and 1 had cataracts (Supplemental Table 4 ).
In New York, the identification of the R145C allele among African-Americans was also an unbiased assessment of the risk associated with the R145C allele, because all subjects with the R145C allele were obtained from a random sample of subjects in the New York Metropolitan Area, recruited to a study regarding lung health. On average, the African-American R145C subjects had 52% significantly greater triglyceride levels compared with the AfricanAmerican controls but no differences in the cholesterol or HDL cholesterol levels and a borderline decrease in LDL cholesterol. A more detailed assessment of a subgroup of the African-American R145C subjects demonstrated that 31% of the population studied had higher levels of small verylow-density lipoprotein particles than the normal range (Supplemental Table 6 ). Elevated levels of small very-lowdensity lipoprotein particles have been associated with an increased risk of coronary artery disease and peripheral arterial disease. 23 It appears, therefore, that the R145C allele is an at-risk allele for mild dyslipidemia, with a subgroup of the R145C heterozygotes developing a more severe dyslipidemia in accordance with other genetic variations, age, diet, body mass index, diabetes status, thyroid hormone levels, and medications. 3, 24 Although HIV infection can be associated with dyslipidemia, 25, 26 no difference was found in the lipid levels between the HIV-positive and HIV-negative R145C African-Americans, and ANOVA analysis demonstrated that HIV status could not explain the elevated triglyceride levels in the R145C heterozygotes.
The overall risk of dyslipidemia conveyed by the R145C allele appears to be mild, and additional epidemiologic * TaqMan was used to identify the R145C allele; all R145C were then sequenced. In the setting of a double mutation, the samples were cloned and sequenced to determine the "cis" or "trans" relation.
† Subjects with self-reported ethnicities from the New York City
Metropolitan Area. z An allele novel to the present study with 2 mutations in the amino acid sequence resulting in substitution of lysine (K) for glutamate (E) at residue 13 and cysteine for arginine at residue 145 (R145C).
x This subject was of African-American-Hispanic mixed ancestry. jj ApoE Philadelphia a double mutant of E13K and R145C on an ApoE3
background; this allele has been previously described. 
Identification of ApoE Variants
DNA was extracted from blood of Qataris with QIAGEN blood kit and from blood of New York samples using AutoGenFlex STAR (Holliston, MA) with the FlexiGene DNA AGF3000 Kit 640 (QIAGEN, Valencia, CA). DNA was quality controlled requiring an A260/A280 ratio of 1.8-2.1, quantified with a NanoDrop spectrophotometer.
To identify ApoE variants in the Qatari population, all ApoE exons and adjacent portions of the introns were amplified by PCR (see Supplemental Table III for details). PCR products were purified with MiniElute 96 UF PCR Purification Kit (QIAGEN) and then sequenced by automated dideoxy sequencing. Sequences were compiled and variations identified using SeqScape 2.5 software (Applied Biosystems, Foster City, CA). All putative variations were verified by manual inspection of the sequence traces.
-3 -New York African-Americans were compared to New York whites for the prevalence of ApoE R145C variants. The rs769455 genotype, corresponding to the ApoE R145C amino acid substitution, was assessed in blood DNA for the 2238 New York City subjects by TaqMan SNP Genotyping Assay (Applied Biosystems). Subjects identified as R145C heterozygotes by this method were further assessed by amplification and sequencing of all of the ApoE coding exons, as described above. In those cases where sequencing identified the ApoE R145C variant plus a second rare variant, the cis or trans relationship of the 2 variants was determined by sequencing multiple cloned PCR products. The PCR product representing the coding region was cloned into the pCR-TOPO vector. A minimum of 9 colonies were assessed by sequencing with M13 universal primers in both directions. The genotype for each clone, representing the amplification product of either allele at random, was compiled using SeqScape 2.5 software.
The 1000G pilot study data includes high-quality genotypes determined from lowcoverage whole-genome sequencing, deep-coverage targeted exome sequencing, and wholegenome SNP array genotyping on 2.5M SNPs. Missing genotypes were imputed and wholegenome SNPs were phased for each individual. Using the 1000G phased and complete data, the allele and haplotype frequency for the three ApoE SNPs was calculated. The three SNPs were rs429358 (GRCh37.chr19:45411941.T>C; C112R), rs769455 (GRCh37.chr19:45412040.C>T; R145C), and rs7412 (GRCh37.45412079.C>T; R158C), with reference haplotype T-C-C referred to as the ApoE E3 gene allele. The rs7412 SNP was used to identify the E2 allele T-C-T and the rs429358 SNP was used to identify the E4 allele C-C-C. We determined the frequency of the 3 known ApoE gene alleles (E2, E3, E4), and then quantified the frequency of the R145C SNP (T at rs769455) on each background, identified respectively as E2R145C (T-T-T), E3R145C (T-T-C), and E4R145C (C-T-C).
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Clinical Phenotypes and Lipid Profiles
Fasting blood samples were collected in ethylenediaminetetraacetic acid tubes and were kept on ice. Plasma was isolated by centrifugation (3000 rpm, 15 min, 4°C). Fresh plasma samples were shipped overnight on ice for lipoprotein subclass profiling by proton NMR spectroscopy on an automated 400 MHz lipoprotein analyzer (Liposcience, Raleigh, NC). Additional fasting serum samples were assessed for very low density lipoprotein (VLDL) and chylomicrons, low density (LDL) and high density (HDL) particle concentrations, mean particle sizes of the various lipid particles, hemoglobin A1C (HbA1C), high sensitivity C-reactive protein (hs-CRP), lipoprotein(a) [Lp(a)], ApoA1, ApoB, thyroid stimulating hormone (TSH) and glucose (Liposcience, Raleigh, NC). Additional fasting blood samples were collected in serum separator tubes containing an inert polyester-based gel and silica particles as clot activators. After blood clotting and centrifugation, serum was assessed by LDL electrophoresis and LDL subfractionation (Berkeley Heart Labs, Alameda, CA).
Nomenclature
The R145C ApoE protein mutation was first described by Rall et al 2 in 2 individuals with hyperlipidemia (Supplemental Table 2 ). It was named "ApoE2*R145C" because the protein migrated with the ApoE2 isotype on isoelectric focusing 2, 3 . This nomenclature was maintained in the limited literature describing this variant, although de Villers et al 4 recognized that the majority of their R145C cases were on the ApoE3, not the ApoE2 allele. In the present study, sequence analysis of the Qatari and New York subjects with the R145C variant demonstrated that the majority of the R145C polymorphisms were on the ApoE3 background (Cys112, Arg158) not the ApoE2 background (Cys112, Cys158), and thus should be appropriately termed "ApoE3R145C."
Among all populations studied, to a far lesser extent, the R145C polymorphism has been observed on the ApoE2, E4, E4.R158C, E4E13K and E3E13K alleles.
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Statistical Analyses
For the fasting lipid studies in the Q3 Qataris and the New York African-Americans, the average levels of triglycerides, cholesterol, LDL-cholesterol and HDL-cholesterol were calculated in 2 ways. First, the mean of each individual was calculated as the sum of all measurements,
given the same weight, and divided by the number of measurements; from these means, the mean ± standard deviation was reported for the cases (R145C) and controls. To calculate the p value, a single factor ANOVA was applied using the averaged values for each of the measures, for each individual. All p values were calculated based on the original scale, except for triglycerides in the New York African-Americans and triglycerides, cholesterol and HDL-cholesterol in the Qataris, which required a log-transformation to be considered normal. Averages and p values for all other parameters were calculated using a single factor ANOVA or a chi-square test. Second, weighted overall means were calculated by weighting the mean value for each individual by the inverse of the (estimated) expected sampling variance, i.e., the variance in mean response.
Weighted overall, case, and control variances were calculated by using the same weights for each of the squared differences from the weighted mean. To calculate the p value, a nested ANOVA was applied using the R package "lme4" (https://r-forge.r-project.org/), where repeated measurements of individuals were considered a nested random factor. For this model, it was not possible to extract an exact p value due to the unclear degrees of freedom. An approximate p value for the test of a difference between cases and controls was therefore extracted using a t-statistic with degrees of freedom equal to the number of individuals minus two. The average values and nested ANOVAs for the New York African-Americans were assessed with and without including HIV status as a fixed covariate. HIV status was not available for the Qatari subjects. Table 1 for an overview of the 228 Qataris from whom the 4 R145C heterozygotes were identified. 2 Genotype identified by sequencing all ApoE exons and flanking introns; all individuals had the Q3 (African) genetic background. 3 BMI = body mass index; listed for controls are the average BMI and standard deviation, the BMI at first lipid profile was used for each individual. 4 Cardiovascular diseases included ventricular hypertrophy, valve disease, cardiomyopathy, coronary artery disease and/or history of myocardial infarction. 5 Thyroid diseases included hyperthyroidism. 6 All data are presented as mean ± standard deviation. HDL = high density lipoprotein cholesterol; LDL = low density lipoprotein cholesterol; average values were calculated from multiple fasting lipid profiles for each patient obtained at different visits. 7 Average ± standard deviation of the average level for each subject; p value is calculated by a single factor ANOVA. 8 Weighted average ± weighted standard deviation of all test results available; p value is calculated by a nested ANOVA. 9 Clinical and demographic data was available for 15 Q3 controls; see Table 1 ; data for cholesterol and triglyceride was available for n=15; data for HDL and LDL was available for n=14. Data for age and BMI are presented as average ± SD; data for all other parameters except for gender are presented as % of n=15. 
Supplemental

54±20
52±14 >0.7 1 In the NYC African-American population, all subjects with the ApoE R145C mutation were on the E3 allele except one that was on E4E13K allele. Data for cholesterol and triglyceride was available for n=30; data for HDL and LDL was available for n=26. 2 The controls were randomly chosen from the African-American population without the ApoE R145C mutation (proven by TaqMan PCR and then by sequencing). Data for cholesterol and triglyceride was available for n=72; data for HDL and LDL was available for n=24. 3 BMI = body mass index; listed is the average BMI and standard deviation, the BMI at first lipid profile was used for each individual. 4 Cardiovascular diseases included ventricular hypertrophy, valve disease, cardiomyopathy, coronary artery disease and/or history of myocardial infarction. 5 Thyroid diseases included hyperthyroidism. 6 Average ± standard deviation of the average level for each subject; p value is calculated by a single factor ANOVA. 7 Weighted average ± weighted standard deviation of all test results available; p value is calculated by a nested ANOVA. 8 p value for BMI and age was calculated using a single factor ANOVA; For all other parameters except for lipid data, a chi-square test was used to calculate the p value. 
